Trials / Completed
CompletedNCT00494299
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 458 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib |
| DRUG | Placebo | Placebo: matching placebo |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2009-07-01
- Completion
- 2010-11-01
- First posted
- 2007-06-29
- Last updated
- 2013-12-20
- Results posted
- 2011-01-20
Locations
75 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT00494299. Inclusion in this directory is not an endorsement.